NANOG and colorectal carcinoma: Inhibition of JMJD2B expression in vitro and in vivo impairs ETBF-induced CSCs properties, through directly binding to and removing transcriptional repressive H3K9me3 marks on the NANOG promoter, which impedes CRC development (Figure 6).